期刊文献+

五个厂家氯雷他定片或胶囊体外溶出度比较 被引量:3

Comparison of dissolution of loratadine tablets or capsules in vitro from five manufacturers
下载PDF
导出
摘要 目的:比较5个厂家的氯雷他定片剂或胶囊剂的溶出度,为临床用药提供参考。方法:采用转篮法进行体外溶出度实验,以紫外分光光度法进行含量测定,计算其累积溶出百分率,并以威布尔方程拟合溶出参数,用方差分析对组间溶出参数进行统计学处理,采用Q检验进行两两检验。结果:5个厂家的氯雷他定片或胶囊的体外溶出度均符合2005年版国家药典标准的规定,但各厂家氯雷他定片或胶囊的溶出度参数m、Kr、T_(50)、T_(30)、T_d、T_(80)间存在显著性差异(P<0.05)。结论:不同厂家氯雷他定片或胶囊的溶出参数存在差异,临床用药时应加以注意。 Objective:To compare the dissolution of loratadine tablets or capsules in vitro from five different pharmaceutical factories and give suggestions for clinical use. Methods : The dissolution tests were carried out with rotating basket and the content of loratadine was determined by UV spectrophotometry. The accumulation dissolution percent was calculated and Weibull formula was used to fit the deta. The dissolution parameters was statistically analyzed by variance analysis and Q test. Results : The dissolution of loratadinc tablets or capsules in vitro from five factories were all in conformity with Chinese Pharmacopoeia (2005 edition). But significant differences of dissolution parameters m ,Kr, T30,T50, Td and T80 were found among the loratadine tablets or capsules from five factories (P 〈 0.05 ). Conclusion: There is a significant difference in dissolution parameters of the loratadine tablets or capsules from five factories, indicating that attention should be paid to their difference in clinical use.
出处 《药学实践杂志》 CAS 2008年第5期350-352,共3页 Journal of Pharmaceutical Practice
关键词 氯雷他定 溶出度 紫外分光光度法 loratadine dissolution UV spectrophotometry
  • 相关文献

参考文献4

二级参考文献19

  • 1MARKHAM A, WAGSTAFF AJ. fexofenadine[J]. Drugs, 1998,55(2):269-274 .
  • 2NACLERIO RM. All allergic rhinitis[J]. N Engl J Med,1991,325(12):860-8 69.
  • 3PHILPOT EE. Safety of second generation antihistamines[J]. Allergy Ast hma Proc,2000,21(1):15-21.
  • 4MONAHAN BP, FERGUSON CL, KILLEAVY ES. Torsade pointers occurring in assoc iation with terfenadine use[J]. JAMA, 1990,264(21):2788-2790.
  • 5GUPTAA K, KATZ HI, SHEAR NH. Drug interactions with intraconazole, fluco nazole and terbinafine and their management[J]. J Am Acad Dermatol, 1999,412 P t 1:237-249.
  • 6SLATER JW, ZECHNICH AD, HARBY DG. Second-generation antihistamine: a comp arative review[J]. Drugs,1999,57(1):31-47.
  • 7LINDQUIST M, EDWARDS IR. Risk of non-sedating antihistamine[J]. Lancet ,1997,349(9061):1322.
  • 8RANKIN AC. Non-Sedating antihistamines and cardiac arrhythmia[J]. Lance t,1997,350(9085):1115-1116.
  • 9HONIG PK, WORTHAN DC, ZAMANI K, et al. Terfenadine-Ketoconazole int eraction[J]. JAMA, 1993,269(12):1513-1518.
  • 10HONIG PK, WOOSLEY RL, ZAMAIN K. Changes in the pharmacokinetics and elec trocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin[J]. Clin Pharmacol Ther,1992,51(2):231-238.

共引文献111

同被引文献23

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部